Gianni Sava Selected Research

imidazolium- bis(imidazole)dimethylsulfoxideimidazotetrachlororuthenate(III) (NAMI-A)

1/2021	Evaluation of NAMI-A Cytotoxic Effects toward Leukemia Cell Lines: A Slippery Ground Giving Misleading Messages.
1/2017	Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A.
8/2016	Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging Properties.
1/2016	Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A.
12/2015	Linking the future of anticancer metal-complexes to the therapy of tumour metastases.
10/2015	RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A.
2/2015	Preclinical combination therapy of the investigational drug NAMI-A(+) with doxorubicin for mammary cancer.
2/2015	Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.
10/2012	CDK1 hyperphosphorylation maintenance drives the time-course of G2-M cell cycle arrest after short treatment with NAMI-A in Kb cells.
4/2011	Metal-based inhibition of poly(ADP-ribose) polymerase--the guardian angel of DNA.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gianni Sava Research Topics

Disease

32	Neoplasms (Cancer) 01/2021 - 07/2002
27	Neoplasm Metastasis (Metastasis) 01/2021 - 07/2002
12	Carcinoma (Carcinomatosis) 10/2015 - 02/2003
4	Breast Neoplasms (Breast Cancer) 08/2017 - 12/2008
4	Adenocarcinoma 11/2007 - 01/2003
3	Colorectal Neoplasms (Colorectal Cancer) 01/2017 - 10/2015
2	COVID-19 12/2021 - 01/2021
2	Thrombocytopenia (Thrombopenia) 12/2021 - 01/2021
2	Hemorrhage 12/2021 - 01/2021
2	Thrombosis (Thrombus) 12/2021 - 01/2021
2	Fatigue 02/2021 - 02/2015
2	Colonic Neoplasms (Colon Cancer) 01/2019 - 10/2015
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2015 - 08/2004
2	Lewis Lung Carcinoma 05/2003 - 02/2003
1	Myocardial Infarction 12/2021
1	Stroke (Strokes) 12/2021
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2021
1	Leukemia 01/2021
1	Nausea 02/2015
1	Constipation 02/2015
1	Diarrhea 02/2015
1	Neutropenia 02/2015
1	Anemia 02/2015
1	Vomiting 02/2015
1	Hyperglycemia 03/2014
1	Diabetic Nephropathies (Diabetic Nephropathy) 03/2014
1	Body Weight (Weight, Body) 01/2013
1	Pancreatic Neoplasms (Pancreatic Cancer) 05/2008
1	Melanoma (Melanoma, Malignant) 04/2008
1	Fibrosis (Cirrhosis) 10/2004

Drug/Important Bio-Agent (IBA)

26	RutheniumIBA 01/2021 - 07/2002
25	imidazolium- bis(imidazole)dimethylsulfoxideimidazotetrachlororuthenate(III) (NAMI-A)IBA 01/2021 - 07/2002
9	Pharmaceutical PreparationsIBA 08/2017 - 07/2004
6	Proteins (Proteins, Gene)FDA Link 01/2016 - 05/2003
6	MetalsIBA 01/2016 - 12/2004
5	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 05/2008 - 02/2003
3	PlatinumIBA 01/2019 - 04/2011
3	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 08/2004
3	RAPTA-TIBA 08/2017 - 12/2008
3	CollagenIBA 10/2015 - 05/2003
3	LigandsIBA 07/2012 - 08/2004
3	Cisplatin (Platino)FDA LinkGeneric 04/2011 - 07/2006
3	Hyaluronic Acid (Hyaluronan)IBA 05/2008 - 07/2004
3	Butyric Acid (Butanoic Acid)IBA 05/2008 - 07/2004
3	matrigelIBA 02/2004 - 12/2002
2	VaccinesIBA 12/2021 - 01/2021
2	BNT162 VaccineIBA 12/2021 - 01/2021
2	ChAdOx1 nCoV-19IBA 12/2021 - 01/2021
2	EnzymesIBA 01/2019 - 02/2015
2	IntegrinsIBA 01/2016 - 10/2015
2	Coordination ComplexesIBA 12/2015 - 04/2011
2	RNA (Ribonucleic Acid)IBA 10/2015 - 12/2013
2	Gemcitabine FDA Link 02/2015 - 02/2015
2	CreatinineIBA 02/2015 - 01/2013
2	FullerenesIBA 01/2015 - 12/2013
2	Muramidase (Lysozyme)IBA 03/2014 - 11/2008
2	Histone Deacetylase InhibitorsIBA 05/2008 - 07/2004
2	GelatinasesIBA 10/2004 - 02/2004
2	Peptide Hydrolases (Proteases)FDA Link 01/2004 - 05/2003
1	Ad26COVS1IBA 12/2021
1	ResveratrolIBA 02/2021
1	AntibodiesIBA 01/2021
1	Platelet Factor 4IBA 01/2021
1	Organometallic CompoundsIBA 01/2019
1	3-hydroxycholest-7-ene-14-carbaldehydeIBA 01/2017
1	Ruthenium CompoundsIBA 08/2016
1	Integrin alpha5beta1IBA 01/2016
1	Platinum Compounds (Compounds, Platinum)IBA 12/2015
1	Focal Adhesion Protein-Tyrosine KinasesIBA 10/2015
1	Transcription Factors (Transcription Factor)IBA 10/2015
1	Conditioned Culture MediaIBA 10/2015
1	Fibronectins (Fibronectin)IBA 10/2015
1	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2015
1	Investigational DrugsIBA 02/2015
1	NitrogenIBA 01/2015
1	Advanced Glycation End ProductsIBA 03/2014
1	Caspase 8 (Caspase-8)IBA 12/2012
1	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2012
1	GoldIBA 04/2011
1	IonsIBA 04/2011
1	TolueneIBA 12/2008
1	Ethylene Glycol (Monoethylene Glycol)IBA 11/2008
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2008
1	Vascular Endothelial Growth Factor DIBA 05/2008
1	Caspase 7IBA 05/2008
1	Vascular Endothelial Growth Factor CIBA 05/2008
1	SurvivinIBA 05/2008
1	ethylenediamine (ethylenediamine dihydroiodide)FDA Link 05/2008
1	Cyclin D1IBA 05/2008
1	ChloridesIBA 04/2008
1	Heavy MetalsIBA 07/2006
1	Biological ProductsIBA 06/2005
1	CytokinesIBA 10/2004
1	Protein Isoforms (Isoforms)IBA 10/2004
1	Capsules (Microcapsules)IBA 10/2004
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 08/2004
1	EstersIBA 08/2004

Therapy/Procedure

4	Therapeutics 12/2015 - 12/2002
1	Drug Therapy (Chemotherapy) 12/2015
1	Oral Administration 11/2008